PetMed Express (NASDAQ:PETS) announced its quarterly earnings results on Sunday. The company reported $0.34 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.40 by ($0.06), MarketWatch Earnings reports. PetMed Express had a net margin of 9.82% and a return on equity of 22.79%. The company had revenue of $71.70 million during the quarter, compared to the consensus estimate of $74.04 million. During the same period in the previous year, the firm posted $0.35 EPS. The business’s quarterly revenue was down 3.5% compared to the same quarter last year.
NASDAQ:PETS traded up $0.77 during trading hours on Tuesday, reaching $30.25. 713,637 shares of the stock were exchanged, compared to its average volume of 758,766. PetMed Express has a twelve month low of $27.60 and a twelve month high of $57.00. The stock has a market cap of $613.20 million, a PE ratio of 20.17 and a beta of 0.70. The firm has a 50 day moving average of $32.63 and a 200 day moving average of $32.70.
The company also recently announced a quarterly dividend, which will be paid on Friday, May 21st. Shareholders of record on Friday, May 14th will be paid a $0.30 dividend. This is a boost from PetMed Express’s previous quarterly dividend of $0.28. The ex-dividend date is Thursday, May 13th. This represents a $1.20 annualized dividend and a yield of 3.97%.
About PetMed Express
PetMed Express, Inc, together with its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, and other health products for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventative, flea and tick preventative, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.
Receive News & Ratings for PetMed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express and related companies with MarketBeat.com's FREE daily email newsletter.